All In Biotech

Drug Trial Radar · NCT06335407

Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Outpatient Study

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Jul 28, 2025

Primary completion

Feb 27, 2027

Study completion Apr 30, 2027

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense; Congressionally Directed Medical Research Programs; VA Connecticut Healthcare System; BioXcel Therapeutics Inc; Yale University; RTI International
First posted
Mar 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501) is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress disorder (PTSD) in an outpatient setting and also shows potential signals of efficacy thereby supporting the conduct of later phase clinical trials.

Conditions

  • Alcohol Use Disorder (AUD)
  • Post Traumatic Stress Disorder (PTSD)

Interventions

  • Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µgDrug

    BXCL 501 40µg will be administered orally, as individual films in the Sub Lingual (SL) space.

  • Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µgDrug

    BXCL 501 80µg will be administered orally, as individual films in the SL space

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Blood Pressure (Systolic and Diastolic) from baseline (pre-treatment) through day 28.Time frame: From day 1 through day 28
  2. Change in anxiety (measured via the State Trait Anxiety Inventory - STAI-6) from baseline (pre-treatment) through day 28.Time frame: From day 1 through 28 days
  3. Number and Proportion of Adverse EventsTime frame: From day 1 through 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • VA Connecticut Healthcare System

    West Haven, Connecticut · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.